 CAMBRIDGE, Mass., Oct. 05, 2022 GLOBE NEWSWIRE -- Immuneering Corporation Nasdaq: IMRX, a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced it will present data on its second program IMM-6-415 in a poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer SITC, taking place November 8-12, 2022 in Boston or virtually. 